***As of 28 December 2021, Novo Nordisk completed its acquisition of Dicerna Pharmaceuticals. This episode was recorded prior to the acquisition on 26 August 2021.***
In this episode of One Step Ahead, Douglas Fambrough, Ph.D., President and CEO at Dicerna Pharmaceuticals, talks us through “RNA interference,” an innovative technique that can target and silence certain disease-causing genes. From kidney-related disease to neurological disorders – and potentially even alcohol use disorder – he asserts that gene-based medicines have the potential to be a safe and effective approach to treating disease. According to Dr. Fambrough, we’re at the early stages of a “big bang” for gene-based medicine, and RNAi is just one of many disruptive technologies set to change the future of healthcare.
This episode was presented by Libby Potter.

Racing to Net Zero, with Iberdrola
22:47

Powering the future of mobility, with Verkor and EIT InnoEnergy
32:55

Accelerating digital manufacturing, with Protolabs
30:51